Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(SPRC) MC $8 mil- low floater with MEGA Pipeline targeting multi billion dollar markets
https://s.yimg.com/uu/api/res/1.2/KPVkf9nPgETriDOtaIIynA--~B/aD02NTQ7dz0xMjEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/5f3749bb3d8b467bfb8040e2c83d9e68">https://s.yimg.com/uu/api/res/1.2/KPVkf9nPgETriDOtaIIynA--~B/aD02NTQ7dz0xMjEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/5f3749bb3d8b467bfb8040e2c83d9e68" />
(APTX) $0.47 --Cash $1.48 per shr --important data readout in the coming days
Aptinyx continues to believe that NYX-2925 can offer a novel therapeutic approach for fibromyalgia. To this end, the company plans to report data from ongoing fibromyalgia phase 2b study in early to mid third quarter.
(APTX) $0.47 --Cash $1.48 per shr --important data readout in the coming days
Aptinyx continues to believe that NYX-2925 can offer a novel therapeutic approach for fibromyalgia. To this end, the company plans to report data from ongoing fibromyalgia phase 2b study in early to mid third quarter.
(ADIL) $1.85 --BIG Ph 3 data tomorrow ---Market cap $47 million ..maybe a good opp to make some quick profit
Adial Pharmaceuticals to Announce Topline Results of ONWARDâ„¢ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
https://finance.yahoo.com/news/adial-pharmaceuticals-announce-topline-results-132500273.html
today announced that it plans to report topline results from the Company’s ONWARD™ Phase 3 clinical trial on Wednesday, July 20, 2022.
(ETON) $2.79 --Halted ----FDA approved their drug
Eton Pharmaceuticals Announces FDA Approval of ZONISADEâ„¢ (Zonisamide Oral Suspension)
https://www.globenewswire.com/news-release/2022/07/18/2480941/0/en/Eton-Pharmaceuticals-Announces-FDA-Approval-of-ZONISADE-Zonisamide-Oral-Suspension.html
(ETON) $2.65 --FDA Decision on Monday --market cap $67 million ...FDA approval could push it to $4 or higher
Eton expects the application (Zonisamide Oral Suspension) to be approved on its newly assigned PDUFA date of July 18th.
(ETON) $2.65 --FDA Decision on Monday --market cap $67 million ...FDA approval could push it to $4 or higher
Eton expects the application (Zonisamide Oral Suspension) to be approved on its newly assigned PDUFA date of July 18th.
(EYEN) MC $60 m --3x PHASE 3 Drugs with imminent readout expected in the coming days ,, there was nice insider buying in last weeks ...The company has already 1 Product under FDA approval process with potential approval in Q4 and another one with NDA filing in 2H if the final phase 3 outcome is positive . This underpriced stock has great potential
insider buying
http://openinsider.com/search?q=eyen
(ADIL) $1.23 --Big Phase 3 data in July if positive this will be a multibagger because of its low vaulation of $29 million and the very large market which they target .
Expects Release of Top-Line Data in July
https://finance.yahoo.com/news/adial-pharmaceuticals-announces-database-lock-131600432.html
The ONWARD trial is expected to serve as a basis for approval of AD04 for the treatment of Alcohol Use Disorder
(EYEN) MC $60 m --3x PHASE 3 Drugs with imminent readout expected in the coming days ,, there was nice insider buying in last weeks ...The company has already 1 Product under FDA approval process with potential approval in Q4 and another one with NDA filing in 2H if the final phase 3 outcome is positive . This underpriced stock has great potential
insider buying
http://openinsider.com/search?q=eyen
(TCON) $1.74 up 26% now
(TCON) $1.55--Phase 3 data soon -massive insider buying ...has very low valuation of $30 million
Insider buying
http://openinsider.com/search?q=tcon
company presentation
https://traconpharma.gcs-web.com/static-files/4125549b-8456-41a4-a93f-f73cf98c2aa2
(TCON) $1.55--Phase 3 data soon -massive insider buying ...has very low valuation of $30 million
Insider buying
http://openinsider.com/search?q=tcon
ZYNE $1.35 RALLYYYYYYYYYYYYYYYY
(ZYNE) $1.07--CHEAP Cannabis play about to breakout
(ADIL) $1.50 -Blockbuster P3 results imminent ( in June) ,heavily underpriced at 35 million valuation
Nears completion of ONWARDâ„¢ Phase 3 pivotal trial of AD04 for the treatment of
Alcohol Use Disorder; on track to report Phase 3 results in the current quarter
(ACER) MC $30 m- FDA Decision in 2 Weeks for Orphan Drug = $$$$$$$$$$$$
"FDA has assigned a PDUFA target action date of June 5, 2022, following its acceptance for filing of the NDA for ACER-001 for the treatment of patients with UCDs"
Monkeypox virus next scam after Covid
WHO Convenes Emergency Meeting As MonkeyPox Virus Goes Global
https://www.zerohedge.com/medical/how-has-monkeypox-suddenly-spread-all-over-globe-lightning-speed
(ACER) $2 / FDA Decision in 2 Weeks / Market cap only 31 million
"FDA has assigned a PDUFA target action date of June 5, 2022, following its acceptance for filing of the NDA for ACER-001 for the treatment of patients with UCDs"
(ACER) $1.85 --FDA Decision in 3 Weeks
FDA has assigned a PDUFA target action date of June 5, 2022, following its acceptance for filing of the NDA for ACER-001 for the treatment of patients with UCDs
(TLIS) $1.15 has HUGE Cash of $8.70 per Share + Covid test approved ...nice reboundplay here
(TLIS) $1.10 has HUGECash of $8.70 per Share + Covid test approved ...nice reboundplay here
(TLIS) $1.17 has $8.70 cash per share + covid test system approved ...low floater with massive upside
(TLIS) $1.17 has $8.70 cash per share + covid test system approved ...low floater with massive upside
a deal with Musks SpaceX
(KOD) $7.70 (has $14+ Cash per share) + 4x PHASE 3 Blockbuster = a pure gift here
insert-text-here
TLIS $1.45--has $8.70 cash per share and covid test approved ..huge reboundplay here
TLIS $1.51 /has $8.70 cash per share + covid test approved = easy double or triple from here
Talis Biomedical Granted FDA Emergency Use Authorization (EUA) for COVID-19 Molecular Point-of-Care Test to Detect SARS-CoV-2
https://finance.yahoo.com/news/talis-biomedical-granted-fda-emergency-130000421.html
TLIS $1.73 UP 14% has $8.70 CASH PER SHARE..
TLIS $1.54 /has $8.70 cash per share + covid test approved = easy double or triple from here
Talis Biomedical Granted FDA Emergency Use Authorization (EUA) for COVID-19 Molecular Point-of-Care Test to Detect SARS-CoV-2
https://finance.yahoo.com/news/talis-biomedical-granted-fda-emergency-130000421.html
TLIS $1.54 /has $8.70 cash per share + covid test approved = easy double or triple from here
Talis Biomedical Granted FDA Emergency Use Authorization (EUA) for COVID-19 Molecular Point-of-Care Test to Detect SARS-CoV-2
https://finance.yahoo.com/news/talis-biomedical-granted-fda-emergency-130000421.html
TLIS $1.54 /has $8.70 cash per share + covid test approved = easy double or triple from here
Talis Biomedical Granted FDA Emergency Use Authorization (EUA) for COVID-19 Molecular Point-of-Care Test to Detect SARS-CoV-2
https://finance.yahoo.com/news/talis-biomedical-granted-fda-emergency-130000421.html
TLIS $1.50--has $8.70 cash per shareand covid test approved ..huge reboundplay here
(TLIS) 1.50 /MC $48 m /Cash $233 m ($8.70 Cash per Share) --Covid test system approved = hot reboundplay
TLIS $1.61 has $8.70 Cash per shr...stock about to breakout